Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective

Clinical Radiology

Volumn 60, Issue 4, 2005, Pages 479-492

  Alzahouri, K ^a   Lejeune, C ^b   Woronoff Lemsi, M C ^c   Arveux, P ^d   Guillemin, F ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b INSERM   (France)

^c Unite Evaluation Medico Economique   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Cost effectiveness; Decision trees; Economics; Fludeoxyglucose F18; Non small cell lung carcinoma; Positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

AGED; ANALYSIS OF VARIANCE; ARTICLE; CALCULATION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; FRANCE; FREQUENCY ANALYSIS; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIFE EXPECTANCY; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINOSCOPY; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MORBIDITY; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REIMBURSEMENT; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

AGED; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DECISION TREES; FRANCE; HUMANS; INSURANCE, HEALTH; LIFE EXPECTANCY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 14844338856     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crad.2004.10.010     Document Type: Article

References (61)

1. F. Menegoz R.J. Black P. Arveux et al. Cancer incidence and mortality in France in 1975-95 Eur J Cancer Prev 6 1997 442-466
2. Institut de veille sanitaire. Evolution de l'incidence et de la mortalité par cancer en France de 1978 à 2000. (Accessed September 30, 2004 at http://www.invs.sante.fr/publications/).
3. S.C. Grondin M.J. Liptay Current concepts in the staging of non-small cell lung cancer Surg Oncol 11 2002 181-190
4. T. Naruke K. Suemasu S. Ishikawa Lymph node mapping and curability at various levels of metastasis in resected lung cancer J Thorac Cardiovasc Surg 76 1978 832-839
5. W.P. Luke F.G. Pearson T.R. Todd et al. Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung J Thorac Cardiovasc Surg 91 1986 53-56
6. R.M. Pieterman J.W. van Putten J.J. Meuzelaar et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography N Engl J Med 343 2000 254-261
7. H. van Tinteren O.S. Hoekstra E.F. Smit et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial Lancet 359 2002 1388-1393
8. J.S. Sloka P.D. Hollett M. Mathews Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada Med Sci Monit 10 2004 MT73-MT80
9. W.J. Scott J. Shepherd S.S. Gambhir Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: A decision analysis Ann Thorac Surg 66 1998 1876-1883
10. K.A. Miles An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by positron emission tomography Australas Radiol 45 2001 9-18
11. S. Kosuda K. Ichihara M. Watanabe et al. Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small-cell lung carcinoma in Japan Ann Nucl Med 16 2002 263-271
12. A. Gugiatti A. Grimaldi C. Rossetti et al. Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-cell-lung-cancer in Italy Q J Nucl Med 48 2004 49-61
13. M. Dietlein K. Weber A. Gandjour et al. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results Eur J Nucl Med 27 2000 1598-1609
14. M. Dietlein W.H. Knapp K.W. Lauterbach et al. Economic evaluation studies in nuclear medicine: The need for standardization Eur J Nucl Med 26 1999 663-680
15. R.G. Halliday J. Darba Cost data assessment in multinational economic evaluations: Some theory and review of published studies Appl Health Econ Health Policy 2 2003 149-155
16. J.G. Dolan A survey of clinicians' opinions regarding the value of published decision analyses as sources of clinically useful information Med Decis Making 17 1997 427-430
17. B.A. Dwamena S.S. Sonnad J.O. Angobaldo et al. Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s-meta-analytic comparison of PET and CT Radiology 213 1999 530-536
18. M.E. Singer K.E. Applegate Cost-effectiveness analysis in radiology Radiology 219 2001 611-620
19. T. Funatsu Y. Matsubara S. Ikeda et al. Preoperative mediastinoscopic assessment of N factors and the need for mediastinal lymph node dissection in T1 lung cancer J Thorac Cardiovasc Surg 108 1994 321-328
20. B.D. Daly J.D. Mueller L.J. Faling et al. N2 lung cancer: Outcome in patients with false-negative computed tomographic scans of the chest J Thorac Cardiovasc Surg 105 1993 904-910
21. K. Takamochi K. Nagai J. Yoshida et al. The role of computed tomographic scanning in diagnosing mediastinal node involvement in non-small cell lung cancer J Thorac Cardiovasc Surg 119 2000 1135-1140
22. H. Hoffmann Invasive staging of lung cancer by mediastinoscopy and video-assisted thoracoscopy Lung Cancer 34 Suppl 3 2001 S3-S5
23. B. Passlick B. Kubuschock W. Sienel et al. Mediastinal lymphadenectomy in non-small cell lung cancer: Effectiveness in patients with or without nodal micrometastases-results of a preliminary study Eur J Cardiothorac Surg 21 2002 520-526
24. S.A. Finkler The distinction between cost and charges Ann Intern Med 96 1982 102-109
25. G. Halter A.K. Buck H. Schirrmeister et al. Lymph node staging in lung cancer using [18F]FDG-PET Thorac Cardiovasc Surg 52 2004 96-101
26. E.M. Toloza L. Harpole D.C. McCrory Noninvasive staging of non-small cell lung cancer: A review of the current evidence Chest 123 2003 137S-146S
27. M.K. Gould W.G. Kuschner C.E. Rydzak et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: A meta-analysis Ann Intern Med 139 2003 879-892
28. E.M. Toloza L. Harpole F. Detterbeck et al. Invasive staging of non-small cell lung cancer: A review of the current evidence Chest 123 2003 157S-166S
29. N.F. Esnaola S.N. Lazarides S.J. Mentzer et al. Outcomes and cost-effectiveness of alternative staging strategies for non-small-cell lung cancer J Clin Oncol 20 2002 263-273
30. R.F. Kelly T. Tran A. Holmstrom et al. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy- d -glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer Chest 125 2004 1413-1423
31. M.Y. Chang D.J. Sugarbaker Surgery for early stage non-small cell lung cancer Semin Surg Oncol 21 2003 74-84
32. R.J. Ginsberg L.D. Hill R.T. Eagan et al. Modern thirty-day operative mortality for surgical resections in lung cancer J Thorac Cardiovasc Surg 86 1983 654-658
33. N. Roeslin G. Morand Complications and mortality of surgery for bronchogenic cancers Rev Pneumol Clin 48 1992 231-236
34. I. Vogt-Moykopf T. Fritz G. Meyer et al. Bronchoplastic and angioplastic operation in bronchial carcinoma: Long-term results of a retrospective analysis from 1973 to 1983 Int Surg 71 1986 211-220
35. H. Wada T. Nakamura K. Nakamoto et al. Thirty-day operative mortality for thoracotomy in lung cancer J Thorac Cardiovasc Surg 115 1998 70-73
36. J.R. Beck J.P. Kassirer S.G. Pauker A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method Am J Med 73 1982 883-888
37. J.R. Beck S.G. Pauker J.E. Gottlieb et al. A convenient approximation of life expectancy (the "DEALE";). II. Use in medical decision-making Am J Med 73 1982 889-897
38. S.V. Moroff S.G. Pauker What to do when the patient outlives the literature, or DEALE-ing with a full deck Med Decis Making 3 1983 313-338
39. I.J. Cybulsky W.F. Bennett Mediastinoscopy as a routine outpatient procedure Ann Thorac Surg 58 1994 176-178
40. Z.T. Hammoud R.C. Anderson B.F. Meyers et al. The current role of mediastinoscopy in the evaluation of thoracic disease J Thorac Cardiovasc Surg 118 1999 894-899
41. H.J. Puhakka Complications of mediastinoscopy J Laryngol Otol 103 1989 312-315
42. E. Bergeal Evalutaion médico-économique de la Tomographie à Emission de Positons: Le projet Champardennais, thèse de Doctorat en médecine Université de Reims 2000 40-58
43. M.V.J. Fauchet Tomographie par émission de positons et oncologie : Technique, clinique, offre industrielle, mise en œuvre RBM 20 1998 113-182
44. S. Schraub P. Arveux M. Mercier et al., Surgical health care patterns and cancer cost: Two studies using population registry data Rev Epidemiol Sante Publique 44 Suppl 1 1996 S33-S39
45. J.E. Siegel M.C. Weinstein L.B. Russell et al., Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine JAMA 276 1996 1339-1341
46. M.F. Drummond T.O. Jefferson Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party BMJ 313 1996 275-283
47. B.J. O'Brien M.F. Drummond R.J. Labelle et al., In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care Med Care 32 1994 150-163
48. C. Siani J.P. Moatti The handling of uncertainty in economic evaluations of health care strategies Rev Epidemiol Sante Publique 51 2003 255-276
49. A. Briggs P. Fenn Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane Health Econ 7 1998 723-740
50. R.C. Viney M.J. Boyer M.T. King et al., Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer J Clin Oncol 22 2004 2357-2362
51. K. McPherson J.E. Wennberg O.B. Hovind Small-area variations in the use of common surgical procedures: An international comparison of New England, England, and Norway N Engl J Med 307 1982 1310-1314
52. P.V. Rosenau Managing medical technology: Lessons for the United States from Quebec and France Int J Health Serv 30 2000 617-639
53. D.C. Cherkin R.A. Deyo J.D. Loeser et al., An international comparison of back surgery rates Spine 19 1994 1201-1206
54. E. Volinn P. Diehr M.A. Ciol et al., Why does geographic variation in health care practices matter? (And seven questions to ask in evaluating studies on geographic variation) Spine 19 1994 2092S-2100S
55. D. Lardinois W. Weder T.F. Hany et al., Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography N Engl J Med 348 2003 2500-2507
56. M.P. MacManus R.J. Hicks J.P. Matthews et al., High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: Implications for radical radiation therapy Int J Radiat Oncol Biol Phys 50 2001 287-293
57. S.G. Stroobants I. D'Hoore C. Dooms et al., Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer Clin Lung Cancer 4 2003 242-247
58. S.K. Cheran J.E. Herndon E.F. Patz Jr Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer Lung Cancer 44 2004 317-325
59. I. Gayed T. Vu M. Johnson et al., Comparison of bone and 2-deoxy-2-[18F]fluoro- d -glucose positron emission tomography in the evaluation of bony metastases in lung cancer Mol Imaging Biol 5 2003 26-31
60. G.V. Gonzalez-Stawinski A. Lemaire F. Merchant et al., A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer J Thorac Cardiovasc Surg 126 2003 1900-1905
61. C.E. Reed D.H. Harpole K.E. Posther et al., Results of the American College of Surgeons Oncology Group Z0050 trial: The utility of positron emission tomography in staging potentially operable non-small cell lung cancer J Thorac Cardiovasc Surg 126 2003 1943-1951